2025 Drug Approvals: Biopharma's Resilience Amidst Challenges
Decision brief
Answer first · skim in under a minute
In 2025, biopharma achieved 55 new drug approvals despite regulatory challenges. This article explores the implications for stakeholders.
2025 Drug Approvals: Biopharma's Resilience Amidst Challenges is best measured with FDA’s own count: CDER approved 46 novel drugs in 2025—34 new molecular entities and 12 biologics—near the recent five-year average and above the long-run historical mean.
Contents10 sections
Key Takeaways
- CDER’s 2025 novel approvals totaled 46 (34 NMEs and 12 biologics), not the inflated 55 figure circulating in some trade summaries.
- 85% (39/46) were first-cycle approvals; 70% (32/46) were first approved in the U.S.
- Half (23/46) carried Orphan Drug Designation; combined with CBER, FDA counted 58 novel approvals.
- Resilience claim is relative: 46 is below 2024’s 50 but still historically strong.
How many novel drugs did FDA approve in 2025?
According to CDER’s annual report Advancing Health Through Innovation: New Drug Therapy Approvals 2025, the center approved 46 novel drugs never before marketed in the United States.
Of those, 34 were new molecular entities and 12 were biologics. CDER notes the total is similar to the average for the last five years and above the historical average of about 38 novel drugs per year since 2007.
What access metrics show “resilience”?
FDA’s published metrics for the 46 novel approvals include:
- First-cycle approvals: 39 of 46 (85%)
- U.S.-first approvals: 32 of 46 (70%)
- Orphan Drug Designation: 23 of 46 (50%)
- CDER plus CBER novel approvals combined: 58 in 2025
Those figures come from the same agency report and the companion novel-approvals materials on FDA Novel Drug Approvals for 2025.
Which therapeutic areas and modalities stood out?
Agency and independent tallies show oncology and hematology remaining large shares of the 2025 list, with small molecules again dominating modality mix. Notable first-in-class examples cited in the CDER report include non-opioid pain therapy and rare-disease products such as treatments highlighted for thymidine kinase 2 deficiency.
Combined CDER/CBER novelty reached 58, reminding investors that gene therapies and vaccines sit outside the CDER-only “46” headline when comparing year-over-year totals.
How should investors read the 46 vs 50 dip?
A four-drug step-down from 2024’s 50 CDER novel approvals is real but does not equal a collapse. The 2025 total remains above weak years such as 2022 and above the long-run historical average FDA cites since 2007.
Portfolio construction should weight first-cycle success rates and U.S.-first share as much as raw counts. PDUFA goal-date performance in the report (44 of 46 met or exceeded for novel approvals) is another resilience signal distinct from approval volume.
What challenges still sit behind the headline count?
Staffing, advisory-committee cadence, and manufacturing inspection capacity can still delay individual programs even when aggregate first-cycle rates look strong. Shortage-driven compounding policy and CNPV process experiments also change go-to-market timing for selected assets.
For BD teams, the actionable read is pipeline quality and CMC readiness, not a narrative that biopharma “sailed through” 2025 without friction.
What remains unproven about “resilience” narratives?
Media claims of “55 new drug approvals” overstate CDER’s novel count and should be discarded. Novel-drug tallies also exclude many supplemental indications, which matter commercially but are not “new drugs.”
Year-ahead 2026 volume is not forecast by the 2025 report; treat forward guidance from sponsors as company-specific, not as FDA volume commitments.
Related NovaPharma coverage
- Vanda tradipitant FDA re-review update
- Why innovation alone is no longer enough in biopharma
- Manufacturing pipeline approvals: what the evidence shows
Frequently Asked Questions
How many novel drugs did CDER approve in 2025?
CDER approved 46 novel drugs in 2025, including 34 new molecular entities and 12 biologics, according to FDA’s New Drug Therapy Approvals 2025 report.
Were most 2025 novel drugs approved on the first review cycle?
Yes. FDA reported that 39 of 46 novel approvals (85%) were first-cycle approvals.
How does 2025 compare with recent years?
FDA described 46 as similar to the recent five-year average and above the historical average of about 38 novel drugs per year since 2007, though below 2024’s 50 CDER novel approvals.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
